Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence to Advance…
Enteris BioPharma announced its entry into a definitive licensing agreement with Cara Therapeutics (Nasdaq: CARA) for Enteris' Peptelligence technology in the ongoing development of an…
Read More...
Read More...
